department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

GLAUKOS Corp ($GKOS) · pharmadog

PUBLIC COMPANY

$GKOSGLAUKOS Corp

Aliso Viejo, CA, USupdated 1h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

13

marketed

1

phase 3

1

catalysts ytd

5

approvals ytd

2

recalls ytd

0

Pipeline(13)

view full pipeline →

pipeline depth13 products

2Preclinical7Phase 21Phase 31Marketed2Unknown

riboflavin 5'-phosphate sodium

Keratoconus

Ocular Hypertension

Prostaglandin F2-alpha receptor

Muscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3

Demodex Blepharitis

Age Related Macular Degeneration

iLution travoprost

Ocular Hypertension

Prostaglandin F2-alpha receptor

Keratoconjunctivitis Sicca (Dry Eye)

Muscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3

iDose Next Generation

triamcinolone acetonide SR

Diabetic Macular Edema

EPIOXA HD/EPIOXA KIT

Upcoming

GLAUKOS Corp earnings

Recent(90d)

earnings (1) · device pma (1)

GLAUKOS Corp earnings

Glaukos Corporation — iStent® Trabecular Micro-Bypass Stent System (PMA supplement)

view all catalysts →

🐶 Hiring Signal

next earnings Jul 29, 2026

No open roles indexed yet — view GLAUKOS Corp jobs →

News

no news has mentioned this company yet

identifiers

ticker

$GKOS

SEC CIK

0001192448

country

US

source

sec_tickers

top tags

Ophthalmology8 Diabetic Macular Edema2

mentioned in

0news items

entity-linker matched

Data sources

SEC EDGAR · openFDA

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase4Travoprost Intraocular Implant + iStent Infiniterecruitingn=150
phase3Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implantrecruitingn=510
phase3Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implantrecruitingn=610
phase2Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitisrecruitingn=250
—Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcgrecruitingn=30
phase2Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconusrecruitingn=100
phase4Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alonerecruitingn=132
phase2A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCEDrecruitingn=84

more trials →

$GKOS147.96-0.26%

$GKOS147.96-0.26%

$GKOS147.96-0.26%

$GKOS147.96-0.26%

Insider activity

source: SEC Form 4

90d open-market buys

$0

0 transactions

90d open-market sells

$246K

4 transactions

net (buys − sells)

−$246K

non-derivative only

open-market buys + sells

Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER1,237 sh @ $116.72−$144K↗
Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER614 sh @ $119.35−$73K↗
Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER210 sh @ $117.45−$25K↗
Apr 10, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER32 sh @ $120.23−$4K↗
Mar 25, 26SELLThurman Alex R.· SVP & CHIEF FINANCIAL OFFICER2,511 sh @ $106.46−$267K↗
Mar 24, 26SELLThurman Alex R.· SVP & CHIEF FINANCIAL OFFICER1,521 sh @ $105.24−$160K↗
Mar 17, 26SELLThurman Alex R.· SVP & CHIEF FINANCIAL OFFICER625 sh @ $99.15−$62K↗
Mar 16, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER460 sh @ $97.33−$45K↗
Mar 16, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER299 sh @ $98.21−$29K↗
Mar 16, 26SELLNavratil Tomas· CHIEF DEVELOPMENT OFFICER272 sh @ $99.05−$27K↗
Feb 19, 26SELLWEISNER AIMEE S· 6,471 sh @ $118.56−$767K↗
Feb 19, 26SELLWEISNER AIMEE S· 5,242 sh @ $116.64−$611K↗
Feb 19, 26SELLWEISNER AIMEE S· 2,153 sh @ $115.69−$249K↗
Feb 19, 26SELLWEISNER AIMEE S· 1,134 sh @ $117.33−$133K↗

routine RSU / option mechanics (6)

Apr 2, 26tax coverBurns Thomas William · CHAIRMAN & CEO7,468 sh
Apr 2, 26tax coverGilliam Joseph E · PRESIDENT & COO3,169 sh
Apr 2, 26tax coverBurns Thomas William · CHAIRMAN & CEO2,469 sh
Apr 2, 26tax coverNavratil Tomas · CHIEF DEVELOPMENT OFFICER1,831 sh
Apr 2, 26tax coverThurman Alex R. · SVP & CHIEF FINANCIAL OFFICER1,589 sh

Apr 2, 26

tax cover

Navratil Tomas · CHIEF DEVELOPMENT OFFICER

1,146 sh